Table 1.
Patient characteristics
| Local recurrence | p value | ||||
|---|---|---|---|---|---|
| + (n = 12) | − (n = 375) | ||||
| n | % | n | % | ||
| Age | 0.065 | ||||
| ≤ 40 | 5 | 41.7 | 71 | 18.9 | |
| > 40 | 7 | 58.3 | 304 | 81.1 | |
| MRI findings before reconstruction | 0.482 | ||||
| Segmental lesion | 11 | 91.7 | 350 | 93.3 | |
| Isolated mass | 1 | 8.3 | 19 | 5.1 | |
| NE | 0 | 0.0 | 6 | 1.6 | |
| Histology | 0.408 | ||||
| DCIS/LCIS | 3 | 25.0 | 84 | 22.4 | |
| IDC/ILC | 5 | 41.7 | 266 | 70.9 | |
| Other | 4 | 33.3 | 25 | 6.7 | |
| Tumor size | 0.470 | ||||
| Is | 3 | 25.0 | 86 | 22.9 | |
| 1 | 4 | 33.3 | 184 | 49.1 | |
| 2 | 5 | 41.7 | 89 | 23.7 | |
| 3 | 0 | 0.0 | 16 | 4.3 | |
| Nodal status | 0.432 | ||||
| 0 | 8 | 66.7 | 301 | 80.3 | |
| 1 | 4 | 33.3 | 65 | 17.3 | |
| 2/3 | 0 | 0.0 | 9 | 2.4 | |
| Stage | 0.842 | ||||
| 0 | 3 | 25.0 | 86 | 22.9 | |
| I | 4 | 33.3 | 158 | 42.1 | |
| II | 5 | 41.7 | 117 | 31.2 | |
| III | 0 | 0.0 | 14 | 3.7 | |
| ER | 0.400 | ||||
| + | 9 | 75.0 | 320 | 85.3 | |
| − | 3 | 25.0 | 55 | 14.7 | |
| PgR | 0.867 | ||||
| + | 9 | 75.0 | 289 | 77.1 | |
| − | 3 | 25.0 | 86 | 22.9 | |
| HER2 | 0.453 | ||||
| + | 3 | 25.0 | 65 | 17.3 | |
| − | 9 | 75.0 | 306 | 81.6 | |
| NE | 0 | 0.0 | 4 | 1.1 | |
| Subtype | 0.552 | ||||
| Luminal A-like | 6 | 50.0 | 235 | 62.7 | |
| Luminal B-like HER2 negative | 3 | 25.0 | 59 | 15.7 | |
| Luminal B-like HER2 positive/HER2 | 3 | 25.0 | 59 | 15.7 | |
| Triple Negative | 0 | 0.0 | 15 | 4.0 | |
| NE | 0 | 0.0 | 7 | 1.9 | |
| Nuclear grade | 0.402 | ||||
| Low/intermediate/high grade DCIS | 3 | 25.0 | 70 | 18.7 | |
| 1 | 3 | 25.0 | 154 | 41.1 | |
| 2/3 | 6 | 50.0 | 125 | 33.3 | |
| NE | 0 | 0.0 | 26 | 6.9 | |
| EIC | 0.981 | ||||
| + | 4 | 33.3 | 115 | 30.7 | |
| − | 4 | 33.3 | 117 | 31.2 | |
| NE | 4 | 33.3 | 143 | 38.1 | |
| Lymphatic vessel invasion | 0.004 | ||||
| + | 9 | 75.0 | 122 | 32.5 | |
| − | 3 | 25.0 | 247 | 65.9 | |
| NE | 0 | 0.0 | 6 | 1.6 | |
| Operation | 0.393 | ||||
| TM/SSM | 10 | 83.3 | 334 | 89.1 | |
| NSM | 1 | 8.3 | 13 | 3.5 | |
| ASM | 1 | 8.3 | 28 | 7.5 | |
| Surgical margin (lateral) | 0.476 | ||||
| + | 1 | 8.3 | 13 | 3.5 | |
| < 2 mm | 0 | 0.0 | 6 | 1.6 | |
| − | 11 | 91.7 | 356 | 94.9 | |
| NE | 0 | 0 | 0 | 0 | |
| Surgical margin (vertical) | 0.007 | ||||
| + | 1 | 8.3 | 22 | 5.9 | |
| < 2 mm | 8 | 66.7 | 104 | 27.7 | |
| − | 1 | 8.3 | 170 | 45.3 | |
| NE | 2 | 16.7 | 79 | 21.1 | |
| Adjuvant PMRT | 1.000 | ||||
| + | 0 | 0.0 | 12 | 3.2 | |
| − | 12 | 100.0 | 363 | 96.8 | |
| Neoadjuvant chemotherapy | 1.000 | ||||
| + | 0 | 0.0 | 21 | 5.6 | |
| − | 12 | 100.0 | 354 | 94.4 | |
| Adjuvant hormonal therapy | 0.340 | ||||
| + | 7 | 58.3 | 268 | 71.5 | |
| − | 5 | 41.7 | 107 | 28.5 | |
| Any chemotherapy ± Trastuzumab | 0.535 | ||||
| + | 5 | 41.7 | 120 | 32.0 | |
| − | 7 | 58.3 | 255 | 68.0 | |
MRI, Magnetic Resonance Imaging; DCIS, Ductal carcinoma in situ; LCIS, Lobular carcinoma in situ; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; EIC, Extensive intraductal component; TM, Total mastectomy; SSM, Skin-sparing mastectomy; NSM, Nipple-sparing mastectomy; ASM, Areola-sparing mastectomy; PMRT, Post-Mastectomy Radiotherapy